Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Jefferies Financial Group lowered their FY2023 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, November 6th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of $4.93 per share for the year, down from their previous estimate of $5.07.
Several other research firms have also commented on RARE. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $75.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. ValuEngine lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Leerink Swann reaffirmed a “positive” rating and set a $85.00 price target (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. Cowen reaffirmed a “buy” rating and set a $62.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday. Finally, Piper Jaffray Companies set a $75.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $71.92.
RARE stock opened at $38.90 on Friday. The firm has a market cap of $2.30 billion, a PE ratio of -5.26 and a beta of 2.15. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.14 and a current ratio of 9.32. The firm’s 50 day moving average price is $42.04 and its 200-day moving average price is $54.48. Ultragenyx Pharmaceutical has a one year low of $36.73 and a one year high of $74.50.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). The firm had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 51.40%. The firm’s quarterly revenue was up 119.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.74) EPS.
Institutional investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $25,000. Cutler Group LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $31,000. First Mercantile Trust Co. increased its position in shares of Ultragenyx Pharmaceutical by 16.9% during the second quarter. First Mercantile Trust Co. now owns 1,151 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 166 shares during the period. Smith Asset Management Group LP increased its position in shares of Ultragenyx Pharmaceutical by 22.6% during the second quarter. Smith Asset Management Group LP now owns 1,680 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 310 shares during the period. Finally, CSat Investment Advisory L.P. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $114,000.
In other news, CEO Emil D. Kakkis bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average price of $43.63 per share, with a total value of $218,150.00. Following the completion of the transaction, the chief executive officer now directly owns 472,479 shares in the company, valued at $20,614,258.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.80% of the stock is owned by insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.